Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrosolv dose-ranging placebo-controlled crossover study in grass pollen-induced allergic rhinoconjunctivitis
2019-002847-62Phase 2Completed
- Sponsor
- Marinomed Biotech
- Start
- Nov 2019
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of tacrolimus in allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by Marinomed Biotech. Primary endpoints: Mean Total Ocular Symptom Score and Safety. Started Nov 2019; status: completed.
02
Drugs
tacrolimus
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2019-002847-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002847-62.